7th May 2019 11:30
LONDON (Alliance News) - Renalytix AI PLC on Tuesday said it commenced a collaboration with University Medical Center Groningen to evaluate KidneyIntelX for early identification and guiding therapeutic treatment of diabetic kidney disease.
The study will assess how effectively KidneyIntelX identifies patients with fast-progressing kidney disease who would benefit from new drug therapies. It will cover 3,500 patients with type II diabetes.
Initial data from the collaboration is expected in early 2020.
Renalytix shares were trading up 4.7% at 178.00 pence each.
Related Shares:
Renalytix Plc